\
&
Contact us
This was 1 year ago
LocationBrussels Expo
ProgrammesThe hydrogen economy will redraw the energy map. There is absolutely no doubt that hydrogen will have a key role in the energy transition, especially to harvest the fast-growing amount of renewable energy. Therefore, in the global race to reach the Paris Agreement targets, hydrogen technologies are increasingly at the centre of the attention and are now considered crucial and lucrative opportunities. The hydrogen’s moment is definitely now!
That’s why more and more companies and investors are prioritising hydrogen. Yet, every business decision carries a risk and to mitigate them connections and knowledge-sharing are key. This event is a melting pot of powerful and influential leaders, policy makers, researchers, and end users each looking for the next big thing. Companies will find customers, investors and partners in the exhibition area as well as have be able to attend thought-provoking conferences.
Attendance to the expo area and the B2B Forum is unlimited for all participants, however seats for the High-Level Policy Conference are limited due to the auditorium restrictions.
More information and registration for visitors, exhibitors, speakers & press.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.